Altre lingue Innoveren Scientific Inc.

Azioni

IVRN

US4041243076

Tempo differito OTC Markets Altri mercati azionari 17:46:52 17/04/2024			Variaz. 5gg	Var. 1 gen.
0,02 ^USD	-33,33%		0,00%	-82,76%

06/03	Innoveren Scientific annuncia la presentazione 510(K) alla Food and Drug Administration federale degli Stati Uniti per Skindisc(Tm) Lite	CI
2023	Innoveren Scientific Inc. riporta i risultati degli utili per il terzo trimestre e i nove mesi conclusi il 30 settembre 2023	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Innoveren Scientific Announces 510(K) Submission to U.S. Federal Food and Drug Administration for Skindisc(Tm) Lite	06/03
Innoveren Scientific Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	15/11
Innoveren Scientific Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	15/11
H-Cyte, Inc. has Changed its Name to Innoveren Scientific Inc	10/07/23
Innoveren Scientific Inc. has Changed its Ticker to IVRN from HCYT	10/07/23
H-CYTE, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	22/05/23
H-CYTE, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	10/05/23
H-CYTE, Inc. Auditor Raises 'Going Concern' Doubt	10/05/23
H-CYTE, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)	18/04/23
H-CYTE, Inc. announced that it expects to receive $0.135 million in funding	12/04/23
H-CYTE, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)	02/03/23
H-CYTE, Inc. announced that it expects to receive $0.3 million in funding	24/02/23
H-CYTE Completes Acquisition of SkinDisc™ Regenerative Tissue Kit from Scion Solutions, LLC	29/12/22
H-CYTE, Inc. (OTCQB: HCYT) completed the acquisition of SkinDisc from Tanya Rhodes, Brock Liden, Spencer T Brown and Spencer T Brown.	29/12/22
H-CYTE, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)	28/12/22
H-CYTE, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	14/11/22
H-CYTE, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22
H-CYTE, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)	07/10/22
H-CYTE, Inc. announced that it has received $0.225 million in funding	29/09/22
H-CYTE Announces Intent to Acquire SkinDisc, Expects to Complete Within 30 Days	19/09/22

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Innoveren Scientific Inc.

Azioni

IVRN

US4041243076

Altre lingue

Filtri